What question did this study set out to answer?

March 13, 2026

Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study

Key Points

To assess the pharmacokinetics of meropenem in critically ill adults receiving ECMO.
Analyzed meropenem dosing in critically ill patients on ECMO.
Administered 1 g doses every 8 hours as a continuous infusion.
Evaluated safety and efficacy of this dosing strategy.
Meropenem showed safe pharmacokinetics in the studied population.
Efficacy maintained with continuous infusion dosage in ECMO patients.
No significant adverse effects reported related to the drug.

Abstract

A meropenem dose of 1 g every 8 h as continuous infusion is safe and efficacious in most critically ill patients receiving ECMO with or without concomitant RRT.

اسأل الذكاء الاصطناعي

Bookmark